An observational study in Frontotemporal Dementia, Behavioral Variant and Alzheimer Disease, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 9 under way, 1 of them phase 3. Alzheimer Disease · Assistance Publique - Hôpitaux de Paris.
Among the 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris, this one is the 13th largest by planned enrollment of the 14 observational ones that give a count, is one of 2 that started in 2026, is one of 14 observational ones, and was the 28th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →9 of the 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–90 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 65+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–85 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 50–90
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 55–85
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 34 is below the median of 200 across 817 observational studies indexed under Alzheimer Disease.
Median enrollment 91 across the 14 interventional studies, 97 across the 14 observational. Of the 19 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
4 of the studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05977712Assistance Publique - Hôpitaux de ParisCircadian Rhythm and Other Factors in Memory Clinic Patients | 2027-03 |
| NCT06501495Assistance Publique - Hôpitaux de ParisLinks Between Cognitive Deficits During Normal or Pathological Aging and Slow Waves Measured in EEG | 2027-04 |
| NCT06582199Assistance Publique - Hôpitaux de ParisPrecision Medicine in Alzheimer's Disease : Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD | 2027-09 |
| NCT06068361Assistance Publique - Hôpitaux de ParisDiagnostic Evaluation of Dementia with Lewy Bodies Using a Multimodal Approach | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This monocentric, non-interventional study (SELFSOC) investigates the relationship between self-awareness and social cognition in patients with behavioral variant frontotemporal dementia (bvFTD) and Alzheimer's disease (AD).
The primary objective is to assess metacognitive efficiency related to social cognitive performance using a computerized facial emotion recognition task combined with confidence judgments. Metacognitive indices (including Mratio) will quantify the correspondence between subjective and objective performance.
Thirty-four participants (17 bvFTD, 17 AD; age 50-80; MMSE ≥20) will complete two study visits involving tasks assessing emotion recognition, theory of mind, and memory.
Self-awareness impairments are common in neurodegenerative diseases, yet their relationship with social cognition remains poorly understood. This study aims to characterize metacognitive processes associated with social cognition in bvFTD and AD, and to determine whether these processes differ across diagnostic groups.
The primary objective is to evaluate metacognitive efficiency during a facial emotion recognition task using trial-by-trial retrospective confidence judgments, allowing computation of Mratio. This index reflects the alignment between perceived and actual performance.
Secondary objectives include: (1) assessing additional metacognitive measures (prospective and global judgments), (2) comparing metacognition between bvFTD and AD, (3) examining correlations between metacognitive judgments and social cognitive performance, (4) testing domain specificity by comparing social cognition and memory, (5) evaluating the effect of task complexity, (6) assessing the impact of performance feedback, (7) comparing subjective versus objective metacognitive assessments, (8) investigating the role of anosognosia in AD, and (9) exploring associations with hypnotic suggestibility.
Participants will attend two visits (\~2 hours each). The first visit includes eligibility assessment, sociodemographic data collection, and a computerized emotion recognition task with metacognitive judgments. The second visit includes additional computerized tasks assessing theory of mind and memory, and an optional hypnotic suggestibility assessment.
Statistical analyses will include between-group comparisons using non-parametric tests, within-subject analyses, and exploratory correlational and regression analyses.
Adult patients diagnosed with behavioral variant frontotemporal lobar degeneration (bvFTD) or Alzheimer's disease (AD) at a mild to moderate stage.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants diagnosed with behavioral variant frontotemporal dementia according to established clinical criteria (Rascovsky et al., 2011). Patients are aged 50-80 years with mild to moderate disease severity (MMSE ≥20).
Behavioral: Computer-based facial expression recognition task · Behavioral: Computerized affective task · Behavioral: UCLA Structured Insight Interview · Behavioral: Barber's Standardized Suggestibility Scale
Participants diagnosed with Alzheimer's disease based on biomarker-supported criteria (A+T+; Jack et al., 2018). Patients are aged 50-80 years with mild to moderate disease severity (MMSE ≥20).
Behavioral: Computer-based facial expression recognition task · Behavioral: Computerized affective task · Behavioral: UCLA Structured Insight Interview · Behavioral: Barber's Standardized Suggestibility Scale
Eighteen facial photographs from the FACES database (Ebner et al., 2010) were selected, each depicting one of six emotions: joy, sadness, disgust, fear, anger, and neutral. For each face, the patient must identify the emotion being expressed by choosing from six verbal labels displayed on the screen.
The task consists of 32 silent black-and-white videos featuring two characters interacting in a social situation, adapted from the Pierre and Marie task (Caillaud et al., 2020). Each video lasts between 8 and 9 seconds and shows one of the two characters experiencing a specific emotion. Patients will be asked to infer the emotion felt by that character. The emotions depicted are either positive or negative and vary in complexity: embarrassment, pride, anger, and surprise (8 videos for each emotion). After each video, the name of an emotion will appear on the screen, and patients will be asked to indicate whether the displayed emotion matches the one felt by the protagonist (half of the options will be congruent and the other half incongruent). The measured variable will be the rate of correct responses.
The UCLA Structured Insight Interview (Mendez \& Shapira, 2011), translated into French, will be used to quantify anosognosia. This is a structured interview, conducted by the investigator, designed to assess patients' awareness of their symptoms in cases of neurodegenerative disease.
The participant, who must keep their eyes closed throughout the administration of the scale, receives a standardized series of suggestions read aloud by the experimenter in a specific order. These suggestions pertain to motor, sensory, verbal, and mnemonic responses (lowering or raising the arm, clenching the hands, feeling thirsty, speech inhibition, immobility, post-hypnotic response, and amnesia).The scale consists of 8 items and is therefore scored on a scale of 0 to 8 : minimum score 0/8 = no suggestibility; maximum score 8/8 = maximum suggestibility.
Metacognitive efficiency during facial emotion recognition (Mratio)
Metacognitive efficiency (Mratio) derived from a computerized facial emotion recognition task with trial-by-trial retrospective confidence judgments. This measure quantifies the correspondence between subjective confidence and objective performance in social cognition.
Time frame: Day 0
Prospective and global metacognitive judgments
Assessment of metacognitive performance using prospective (pre-task) and global (post-task) confidence judgments related to social cognitive tasks.
Time frame: Day 0, with the second evaluation taking place between Day 1 and Day 20.
Between-group differences in metacognitive efficiency
Comparison of metacognitive indices (including Mratio) between bvFTD and Alzheimer's disease groups during social cognition tasks.
Time frame: Day 0, with the second evaluation taking place between Day 1 and Day 20
Association between metacognition and social cognition performance
Correlation between metacognitive judgments and objective performance on social cognition tasks (emotion recognition and theory of mind).
Time frame: Day 0, with the second evaluation taking place between Day 1 and Day 20
Domain specificity of metacognition (social cognition vs memory)
Comparison of metacognitive efficiency indices (Mratio) between social cognition tasks and memory tasks.
Time frame: A single evaluation conducted between Day 1 and Day 20
Effect of task complexity on metacognitive performance
Comparison of metacognitive performance across tasks of varying complexity (low-level emotion recognition vs higher-level theory of mind).
Time frame: A single evaluation conducted between Day 1 and Day 20
Effect of feedback on metacognitive adjustment
Evaluation of changes in metacognitive judgments following feedback on actual performance.
Time frame: Day 0, with the second evaluation taking place between Day 1 and Day 20
Subjective versus objective metacognitive assessment
Comparison between questionnaire-based (subjective) and task-based (objective) metacognitive measures and their relationship with social cognition.
Time frame: Day 0, with the second evaluation taking place between Day 1 and Day 20
Impact of anosognosia on social cognition in Alzheimer's disease
Comparison of social cognitive and metacognitive performance between Alzheimer's disease patients with and without anosognosia.
Time frame: Day 0, with the second evaluation taking place between Day 1 and Day 20
Association between hypnotic suggestibility and metacognition
Exploration of the relationship between hypnotic suggestibility scores and metacognitive performance in bvFTD and AD patients.
Time frame: A single optional evaluation conducted between Day 1 and Day 20
Plan to share: Undecided
Start is estimated for Apr 2026; primary completion for Dec 2027, 20 months later.
Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 20 months is below that.
Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →